Benjamin Carr, Ph.D. 👨🏻💻🧬<p><a href="https://hachyderm.io/tags/DEA" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>DEA</span></a> to reclassify <a href="https://hachyderm.io/tags/marijuana" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>marijuana</span></a> as a lower-risk drug, reports say<br>Marijuana's move to <a href="https://hachyderm.io/tags/schedule3" class="mention hashtag" rel="nofollow noopener" target="_blank">#<span>schedule3</span></a> in the ranks of ketamine, testosterone, and products containing less than 90 milligrams of codeine, would be a nod to its potential medical benefits and would shift federal policy in line with many states. To date, 38 states have already legalized medical marijuana. <a href="https://arstechnica.com/science/2024/04/dea-to-reclassify-marijuana-as-a-lower-risk-drug-reports-say/" rel="nofollow noopener" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">arstechnica.com/science/2024/0</span><span class="invisible">4/dea-to-reclassify-marijuana-as-a-lower-risk-drug-reports-say/</span></a></p>